In its third-quarter 13F filing, Banyan Capital Management Inc. reported the initiation of a new position in Johnson & Johnson, purchasing 3,853 shares valued at approximately $714,000. This stake now represents roughly 0.3% of Banyan’s overall portfolio, ranking J&J as the firm’s 22nd largest holding. The strategic timing of this entry coincides with J&J’s 9.1% year-over-year revenue growth in Q4 and EPS stability at $2.46, factors that likely influenced Banyan’s decision to diversify into a large-cap healthcare leader.

Other major institutions also adjusted their J&J exposures during the same period. Norges Bank added a brand-new $4.88 billion stake in Johnson & Johnson, while Vanguard increased its position by 3.1 million shares (a 1.3% lift) to hold over 237 million shares worth $36.2 billion. Geode Capital Management and Legal & General Group Plc expanded their holdings by 2.1% and 6.2% respectively, collectively adding more than 2.3 million shares. These moves highlight continued confidence among large asset managers in J&J’s diversified revenue streams and stable dividend profile.

Positive momentum for J&J’s pipeline was underscored by the European CHMP’s positive opinion on the AKEEGA combination for BRCA-mutant prostate cancer, enhancing upside to future oncology revenues. On the analyst front, Daiwa Capital Markets and Scotiabank raised their price targets and maintained Outperform ratings, while Morgan Stanley upgraded the stock based on a stronger growth outlook. Meanwhile, a U.S. judge’s dismissal of a fraud claim related to the talc settlement removed a near-term legal overhang, although commentators caution that broader litigation remains unresolved.